Neurocrine Biosciences News

NBIX's Elagolix Moving Forward By: Jason Napodano, CFA 2 ) Share Just recently, Neurocrine Bio presented results from the full twelve month analysis of the Petal-603 study, which includes data from the six months on treatment and six months follow-up period.

The first clinical abstract presentation reviews the results of a Phase I study in which elagolix was evaluated over six weeks in 60 healthy premenopausal women.

Neurocrine Biosciences Inc. closed 10 percent higher Monday after the company announced additional positive results from its Phase 2b clinical trial.

Neurocrine Announces Full Year Results from 603 Study of Elagolix for Treatment of Endometriosis Pain Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time SAN ...

It is now my pleasure to turn this call over to Mr. Kevin Gorman. Please go ahead, sir.

Neurocrine Biosciences, Inc. announced today staff reductions of approximately 60 employees, as a part of its restructuring program to focus the Company's efforts on its clinical programs and pre-clinical development leads.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, May 5th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and April earnings reports.

PeopleandPicks.com is Zacks' Community Website Find great stocks and great stock pickers in our online community.

A potential problem for Neurocrine, however, is that one of the endpoints that came up short was the primary, or main goal, of the study, while another was an endpoint suggested by the U.S. Food and Drug Administration.

Neurocrine Announces Top-Line Results From 702 Study of Elagolix for Treatment of Endometriosis Pain SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.